We are live on ! Find out more
AERI

Aerie Pharmaceuticals
AERI

Delisted

AERI was delisted on the 18th of November, 2022.

Back to rankings

176 hedge funds and large institutions have $2.96B invested in Aerie Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 75 increasing their positions, 45 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 45

66% more call options, than puts

Call options by funds: $26.2M | Put options by funds: $15.8M

4% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 25

1% more funds holding

Funds holding: 175 → 176 (+1)

0% more capital invested

Capital invested by funds: $2.94B → $2.96B (+$11.6M)

0% more funds holding in top 10

Funds holding in top 10: 10 → 10 (0)

Holders
176
Holders Change
+1
Holders Change %
+0.57%
% of All Funds
4.02%
Holding in Top 10
10
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.23%
New
26
Increased
75
Reduced
45
Closed
25
Calls
$26.2M
Puts
$15.8M
Net Calls
+$10.4M
Net Calls Change
+$24.3M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$88.8M
2
DM
Deerfield Management
New York
+$67.9M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$30.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$28.1M
5
NHAS
Novo Holdings A/S
Denmark
+$18.1M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$42.7M
2
PHS
PFM Health Sciences
California
-$29.7M
3
PC
PointState Capital
New York
-$19M
4
HM
HealthCor Management
New York
-$18.1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$9.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
176
Federated Hermes
Pennsylvania
$1K -$807K -12,547 -100%
PC
177
PointState Capital
New York
– -$19M -281,600 Closed
GAMA
178
Graticule Asia Macro Advisors
New York
– -$7.4M -109,500 Closed
Alyeska Investment Group
179
Alyeska Investment Group
Illinois
– -$5.69M -84,288 Closed
BI
180
Boulegeris Investments
Georgia
– -$4.5M -66,540 Closed
Parallax Volatility Advisers
181
Parallax Volatility Advisers
California
– -$4.18M -61,946 Closed
BBA
182
Baker Bros. Advisors
New York
– -$4.06M -60,155 Closed
CM
183
Caption Management
Oklahoma
– -$2.63M -39,000 Closed
DC
184
Diametric Capital
Massachusetts
– -$2M -29,629 Closed
HCM
185
Harvey Capital Management
Florida
– -$508K -7,525 Closed
AB
186
Amalgamated Bank
New York
– -$368K -5,441 Closed
TI
187
Trexquant Investment
Connecticut
– -$365K -5,401 Closed
VF
188
Virtu Financial
New York
– -$318K -4,709 Closed
Creative Planning
189
Creative Planning
Kansas
– -$284K -4,200 Closed
AQR Capital Management
190
AQR Capital Management
Connecticut
– -$282K -4,176 Closed
EMG
191
Ellington Management Group
Connecticut
– -$223K -3,300 Closed
SG Americas Securities
192
SG Americas Securities
New York
– -$115K -1,708 Closed
JG
193
Jefferies Group
New York
– -$95K -1,400 Closed
PIA
194
Piedmont Investment Advisors
North Carolina
– -$42K -618 Closed
CIBC Private Wealth Group
195
CIBC Private Wealth Group
Georgia
– -$34K -500 Closed
GBBWRPM
196
Genovese Burford & Brothers Wealth & Retirement Plan Management
California
– -$32K -472 Closed
LF
197
Lee Financial
Texas
– -$14K -200 Closed
SO
198
STRS Ohio
Ohio
– -$12.9K -200 Closed
CF
199
Centaurus Financial
California
– -$7K -100 Closed
PHK
200
Point72 Hong Kong
Hong Kong
– -$1K -17 Closed
4 5 6 7
8

AERI Hedge Fund Activity: Q3 2018 in Review

176 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2018, worth a combined $2.96B — up 0.39% from $2.94B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new AERI positions and 25 closed out — a net gain of 1 holder — while 75 added to existing stakes and 45 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $88.8M. The largest seller was OrbiMed, cutting an estimated $42.7M.

  • 176 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2018, up from 175 in Q2 2018.
  • Funds reported $2.96B of Aerie Pharmaceuticals stock for Q3 2018, up 0.39% quarter-over-quarter.
  • 26 funds opened new Aerie Pharmaceuticals positions in Q3 2018 and 25 closed out, a net change of +1 holder.
  • The largest Aerie Pharmaceuticals buyer in Q3 2018 was Citadel Advisors, an estimated $88.8M added.
  • The largest Aerie Pharmaceuticals seller in Q3 2018 was OrbiMed, an estimated $42.7M sold.

Based on aggregated 13F filings for Q3 2018.